Apyx Medical Corporation
APYX Healthcare Medical Devices
Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024. In the quarter to June 2026, revenue grew 22.1%, EPS grew 22.2%, free cash flow fell 137.4% and total debt rose 2.74%, each against the same quarter a year earlier.
Follow APYX
Apyx Medical Corporation (APYX) EV/Sales
As of 16 October 2026, Apyx Medical Corporation (APYX) trades at a EV/Sales of 2.2×. Over the past ten years it has ranged from 0.7× (November 2022) to 13.1× (November 2021); the current reading is higher than 31% of that period. That is in line with the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.9× | 111.00% |
| FY2024 | 1.4× | (19.52%) |
| FY2023 | 1.7× | 0.25% |
| FY2022 | 1.7× | (79.48%) |
| FY2021 | 8.4× | 14.14% |
| FY2020 | 7.4× | (9.32%) |
| FY2019 | 8.2× | (2.69%) |
| FY2018 | 8.4× | 0.00% |
| FY2017 | 8.4× | 0.00% |
| FY2016 | 8.4× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.7× | 17.25% |
| Mar 2026 | 3.1× | 5.69% |
| Dec 2025 | 2.9× | 33.81% |
| Sep 2025 | 2.2× | (2.94%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QTRX Quanterix Corporation compare | 0.3× |
| LUNG Pulmonx Corporation compare | 0.7× |
| OWLT Owlet, Inc. compare | 0.9× |
| ZOMDF Zomedica Corp. compare | 0.9× |
| MXCT MaxCyte, Inc. compare | 1.2× |
| APYX Apyx Medical Corporation | 2.2× |
| HYPR Hyperfine, Inc. compare | 2.6× |
| LUCD Lucid Diagnostics Inc. compare | 14.3× |
| SERA Sera Prognostics, Inc. compare | 822× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)